France, Germany suspends AstraZeneca Covid jabs.
Two major European super powers France and Germany have suspended AstraZeneca Covid-19 vaccine, pending a review of its safety by the European Medicines agencies
President Emmanuel Macron said on Monday that France was suspending the use of the AstraZeneca Covid-19 vaccine, pending a review of its safety.
“The decision has been made… to suspend the use of the AstraZeneca vaccine as a precaution, hoping that we can resume it quickly if the judgement of the EMA allows it,” Macron told a press conference, adding that an announcement by the EMA was expected on Tuesday afternoon.
“We have a simple guide, to be informed by science and the competent health authorities and to do it as part of a European strategy,” he said.
He said the suspension was, for now, effective “until tomorrow (Tuesday) afternoon” when the EMA should deliver its opinion.
Several European countries, including Germany, Ireland, the Netherlands, have suspended usage of the shot, which was jointly developed with the University of Oxford, after reported blood clotting incidents in Europe.
The decision reverses previous guidance from French health authorities to continue using the jab and came just a day after French Prime Minister Jean Castex had defended the vaccine.
“At this stage, we must have confidence in this vaccine,” Castex said on Sunday.
“If not, we’ll have delays with our vaccinations and French people will be less protected and the health crisis will last longer.”
Speaking alongside Macron at the press conference in southwest France, Spanish Prime Minister Pedro Sanchez announced no change for Spain, but said it was important “to give a message of guarantee and safety to the whole of the European population regarding the vaccination process.”
Macron also said that the French government would have “decisions to take” in the next few days in order to control the spread of Covid-19 cases after an uptick in cases and a rise in hospitalisations.
“We will probably have new decisions to take in the coming days,” Macron said.
He said the government needed to look at “the reality of the epidemic, town by town, region by region: it’s what we are doing.”
Hospitals in the Paris region are close to capacity, with patients being transferred out of the capital region to other parts of France, while other hotspots of infection are in the north around Calais and the Cote d’Azur.
Macron decided against a third national lockdown at the end of January, deciding instead to continue with a policy of a 6:00 pm nation-wide curfew and a partial shutdown of bars, restaurants and other social and entertainment meeting places.
Meanwhile Germany on Monday also halted the use of AstraZeneca’s coronavirus vaccine after reported blood clotting incidents in Europe, saying that a closer look was necessary.
“After new reports of thromboses of the cerebral veins in connection with the vaccination in Germany and Europe, the PEI considers further investigations to be necessary,” the health ministry said, referring to a recommendation by the country’s vaccine authority, the Paul Ehrlich Institute.
“The European Medicines Agency EMA will decide whether and how the new findings will affect the approval of the vaccine,” it added.
Several European countries, including Ireland and the Netherlands, have suspended usage of the shots, which were jointly developed with the University of Oxford.
German Health Minister Jens Spahn said seven cases of cerebral vein thrombosis had been reported, and that while this is a “very low risk” compared to the 1.6 million jabs already given in the country, it would be above average if confirmed to be linked to the vaccine.
“The decision today is a purely precautionary measure,” said Spahn, adding that he hoped EU medicines regulator EMA would deliver guidance within the week after examining the cases.
Both the British-Swedish company and Oxford have said there was no link between their vaccine and blood clotting.
AstraZeneca had said at the weekend that the 15 incidences of deep vein thrombosis (DVT) and 22 events of pulmonary embolism reported among those given the vaccine was “much lower than would be expected to occur naturally in a general population”.
The vaccine has been widely used in Britain’s inoculation campaign, but in the European Union, a rollout using the jabs has been slowed down by delivery problems.